ARCH Venture Partners — 2018 Investments
7 investments dated 2018 · listed companies and verified rows first · show all
Beam Therapeutics develops gene-editing medicines, particularly base editors and precision genome editing technologies, to create lifelong cures for patients with serious genetic diseases.
BiotechDeep TechMedical DevicesCambridge, US
David R. Liu(Founder and Inventor)J. Keith Joung(Founder and Inventor)Feng Zhang(Founder and Inventor)CAROLE HO(Director)John Evans(Executive Officer, Director)MARK FISHMAN(Director)
Board seatRobert NelsenKristina Burow· per SEC Form D
Gossamer Bio is a clinical-stage biopharmaceutical company developing seralutinib, an investigational drug candidate for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
BiotechDigital HealthMedical DevicesSan Diego, US
Bryan Giraudo(Executive Officer)Faheem Hasnain(Executive Officer, Director)Russell Cox(Director)Renee Gala(Director)Laura Carter, Ph.D.(Executive Officer)Christian Waage(Executive Officer)
Board seatKristina BurowRobert Nelsen· per SEC Form D
GRAIL develops the Galleri blood test for multi-cancer early detection using next-generation sequencing and machine learning to screen for multiple deadly cancer types before symptoms appear.
AI & Machine LearningBiotechHealthtechMedical DevicesMenlo Park, US
Joshua Ofman, MD, MSHS(Chief Executive Officer)Aaron Freidin(Executive Officer)Josh Ofman(Executive Officer)Robert Ragusa(Executive Officer, Director)Jose Baselga(Director)Kaye Foster-Cheek(Director)
Board seatRobert Nelsen· per SEC Form D
San Francisco, US
Board seatRobert NelsenKristina BurowVicki Sato· per SEC Form D
Sana is a biotech company developing engineered cell medicines, including gene therapies for gene modification and delivery, cell replacement therapies using stem cell biology, and manufacturing solutions to improve patient access to these treatments.
BiotechHealthtechMedical DevicesSeattle, US
Steve Harr(President and Chief Executive Officer)
Board seatRobert Nelsen· per SEC Form D
Cambridge, US
Board seatRobert NelsenVicki Sato· per SEC Form D · $11.4M raise · filed Feb 2018
KSQ Therapeutics develops eTIL therapies—engineered tumor-infiltrating lymphocyte treatments for solid tumors—using its proprietary CRISPRomics platform to identify and target novel therapeutic candidates through genome-wide CRISPR/Cas9 functional genomic screens.
AI & Machine LearningBiotechMedical DevicesCambridge, US
GEORGE GOLUMBESKI(Director)RICHARD A. MOSCICKI, PH.D.(Director)ALAN L. CRANE(Director)JAMES GILBERT(Director)JOHN TRZUPEK, PH.D.(TREASURER, SECRETARY & CHIEF FINANCIAL OFFICER)DAVID P. MEEKER, M.D.(PRESIDENT AND CHIEF EXECUTIVE OFFICER)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.